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Abstract
Background & Aims: Farnesoid X receptor (FXR, NR1H4) is a ligand-activated transcription factor, belonging to the nuclear
receptor superfamily. FXR is highly expressed in the liver and is essential in regulating bile acid homeostasis. FXR deficiency
is implicated in numerous liver diseases and mice with modulation of FXR have been used as animal models to study liver
physiology and pathology. We have reported genome-wide binding of FXR in mice by chromatin immunoprecipitation -
deep sequencing (ChIP-seq), with results indicating that FXR may be involved in regulating diverse pathways in liver.
However, limited information exists for the functions of human FXR and the suitability of using murine models to study
human FXR functions.
Methods: In the current study, we performed ChIP-seq in primary human hepatocytes (PHHs) treated with a synthetic FXR
agonist, GW4064 or DMSO control. In parallel, RNA deep sequencing (RNA-seq) and RNA microarray were performed for
GW4064 or control treated PHHs and wild type mouse livers, respectively.
Results: ChIP-seq showed similar profiles of genome-wide FXR binding in humans and mice in terms of motif analysis and
pathway prediction. However, RNA-seq and microarray showed more different transcriptome profiles between PHHs and
mouse livers upon GW4064 treatment.
Conclusions: In summary, we have established genome-wide human FXR binding and transcriptome profiles. These results
will aid in determining the human FXR functions, as well as judging to what level the mouse models could be used to study
human FXR functions.
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Introduction
Farnesoid X receptor (FXR, NR1H4) is a ligand activated
transcription factor belonging to the nuclear receptor (NR)
superfamily [1], and is highly expressed in the liver, intestine,
and kidney, both in humans and rodents [2]. Bile acids (BAs) are
the endogenous ligands of FXR [3]. FXR mainly functions as the
BA sensor by regulating genes that are critically involved in BA
homeostasis, including BA biosynthesis, conjugation, and entero-
hepatic circulation [4]. In addition, it has been shown that FXR is
also involved in lipid and glucose homeostasis, inflammation, and
tumorigenesis [4–7]. FXR normally forms a heterodimer with
retinoid X receptor alpha (RXRa) and binds to DNA elements as
FXR response elements (FXRREs) [1]. The most common DNA
motif bound by FXR is an inverted repeat separated by one
nucleotide (IR1). Upon ligand activation, the heterodimer
normally activates the expression of its target genes.
Chromatin immunoprecipitation - deep sequencing (ChIP-seq)
analysis has been widely used to study the functions of various
NRs, including androgen receptor (AR), estrogen receptor alpha
(ERa), glucocorticoid receptor (GR) etc. [8–10]. This approach
has aided in discovering novel pathways regulated by these NRs.
We and others have reported the genome-wide binding analysis
of FXR in mice [11–13]. These studies suggest broad functions of
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mouse FXR as well as novel molecular mechanisms, by which
FXR regulates its target genes. 1st, FXR could bind to multiple
sites within a known FXR target gene. For example, FXR binds to
both the promoter and 39 gene regulatory regions of the Nr0b2
gene, which encodes small heterodimer partner (SHP) [11], and
this pattern of binding likely enhances chromatin interaction and
subsequent gene expression [14]. 2nd, many new target genes of
FXR are identified in the liver and/or intestine, including the
Sqstm1 gene, which encodes the protein p62, an important
component of autophagy [15]. 3rd, FXR cooperates with other
transcription factors, most likely orphan nuclear receptors, to
modulate transcription of genes involved in specific biological
processes. For exp., FXR and LRH-1 (liver receptor homolog-1)
co-regulate genes involved in lipid homeostasis [16,17]. 4th, FXR
elicits tissue-specific binding patterns, indicating differential
regulation of chromatin structures as well as FXR functions
among different organs/cells. 5th, FXR binding could suppress
gene expression, which could be altered during disease state, such
as obesity [13]. Taken together, these studies suggest that FXR
may regulate diverse physiological and pathological processes in
mice, underlying that tissue- or even pathway-specific modulations
of FXR may provide better treatment strategies to various lipid-
and BA-associated diseases. Indeed, recent literatures have
highlighted FXR as a potential therapeutic target for different
metabolic diseases, such as parenteral nutrition associated
cholestasis [18], vertical sleeve gastrectomy [19], and more
commonly nonalcoholic steatohepatitis (NASH) [20,21], while
only limited treatment options are currently available for these
diseases.
To date, the binding of human FXR in primary human
hepatocytes (PHHs) or hepatoma cell lines has been characterized
to limited genes, including ABCB4 (ATP-binding cassette, sub-
family B, member 4), ABCB11, FGF19 (fibroblast growth factor
19), ICAM1 (intercellular adhesion molecule 1), and NR0B2
[4,22–25]. However, the genome-wide FXR binding profile in
humans is not yet available. More importantly, little information is
known about species similarities and differences in terms of FXR
binding between humans and mice, which are needed urgently to
determine to what degree the murine models can be used to study
the role of FXR in various physiological and/or pathological
conditions.
In this study, using ChIP-seq and RNA-seq techniques, we
determined the genome-wide binding and transcriptome profiling
of human FXR in PHHs. We compared and contrasted the
binding patterns and gene regulation profiles of FXR between
human and mouse livers.
Materials and Methods
Cells and Treatment
Primary human hepatocytes (PHHs) used in this study were
obtained through the Liver Tissue Cell Distribution System from
the University of Pittsburgh [26,27]. Only diagnostic and
demographic information were obtained and provided by the
supplier, no identifier was obtained. Comprehensive information
of the PHH donors received in this study was listed in Table S1.
PHHs were cultured in 37uC, 5% CO2 upon arrival. Three hours
later, medium were refreshed with serum-free HMM Hepatocyte
Maintenance Medium supplemented with dexamethasone, insulin,
and GA-1000 (Lonza, Switzerland). Next morning, cells were
treated with 5 mM GW4064 [11], a synthetic FXR agonist, or
control vehicle, DMSO. Cells were collected for chromatin and
RNA isolation at 1 or 24 hours after the treatment, respectively.
RNA was isolated using TRI Reagent (Invitrogen, CA), according
to the manufacture’s instruction. FXR activation was confirmed
by the induction of known human FXR target genes using Reverse
Transcriptase (RT) quantitative PCR (RT-qPCR). Primer se-
quences were listed in Table S2.
Chromatin Immunoprecipitation
One hour after GW4064 treatment, cells were fixed in 1%
formaldehyde for 10 minutes, followed by quenching with glycine
and rinsing with cold PBS. Afterwards, cells were collected and
lysed. Nuclei were released and sonicated into 200–700 base-pair
(bp) DNA fragments. Aliquot chromatin was incubated overnight
with 5 mg anti-FXR antibody (1:1 mixture of sc-1204x and sc-
13063x, ChIP grade) (Santa Cruz Biotechnology, CA), or control
rabbit immunoglobulin G (rIgG, sc-2027) (Santa Cruz Biotech-
nology, CA). Chromatin-antibody complex were pulled down with
prewashed Dyna beads (Invitrogen, CA), washed and eluted. DNA
fragments associated with FXR or control antibodies were eluted
and purified. Input genomic DNA was obtained through similar
elution and purification procedures. Quality of ChIP assay was
confirmed by qPCR with primers amplifying known FXRREs of
human FXR target genes (promoter regions of BSEP (bile salt
export pump) and OST-b (organic solute transporter beta) as well
as the negative control (promoter region of IL-8 (interleukin-8).
Primer sequences were listed in Table S2. PHH samples from
four donors, with good FXR activation and pull-down efficiency,
were selected to pool together for the generation of sequencing
libraries (Table S1).
Sequencing Library Preparation
Equal amounts of chromatin from the selected four PHH
donors were pooled together, followed by ChIP assay to generate
DNA for ChIP-seq library preparation. Equal amounts of RNA
from the selected PHHs were pooled together as well for RNA-seq
library preparation. DNA and RNA sequencing libraries were
prepared using the Illumina TrueSeqTM DNA and RNA Sample
Prep Kit (Illumina, CA), respectively. The quality of all library
samples was confirmed by Agilent Bioanalyzer (Agilent Techno-
logics, CA) before the sequencing reactions. For ChIP-seq, purified
library DNA ranging from 400 to 500 bp was fractionated on an
agarose gel, followed by extraction and purification before
sequencing. All libraries were sequenced 100 bp paired-end on
Illumina HiSeq2000 sequencing system.
ChIP-seq Data Analysis
Genome Analyzer Pipeline Software (Illumina, CA) were used
for both primary image data files processing and base calling. All
sequenced paired-end reads were aligned to Homo sapiens version
19 (hg19) reference genome using bowtie (version 0.12.7) [28].
Only uniquely mapped reads were included. Regions with read
enrichment were detected using Model-based Analysis of ChIP-
Seq (MACS v 1.4.1) method [29]. By comparing with the rIgG
background, non-specific peaks with false discovery rate (FDR)
greater than 0.1 were eliminated. Identified peaks were further
split by Mali Salmon’s Peak Splitter (http://www.ebi.ac.uk/
bertone/software.html) and filtered by p-value of Poisson distri-
bution lower than 1025. Peaks were annotated using R packages
(http://www.r-project.org) based on the ENSEMBL version 65
human genes.
Motif Analysis for ChIP-seq
For each ChIP-seq dataset, the sequences for the summit
regions (201 bp), spanning 100 bp up and downstream from the
summit of each peak, were retrieved. The top 500 sequences with
Genome-Wide Analysis of FXR Targets in PHHs
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the highest peak score were selected for motif analysis based on
MEME (Multiple Em for Motif Elicitation) [30].
ChIP-seq Validation
To validate the ChIP-seq results, we first identified the IR-1 site
for each peak, which was located inside the peak summit regions
(201 bps) used for motif analysis. Then the genome sequences
spanning the IR-1 sites were retrieved to design qPCR primers.
ChIPed DNA from individual donors and pooled samples were
used for qPCR validation. The primer sequences were listed in
Table S2.
Microarray
C57BL/6J (hereafter referred to as wild type (WT)) mice (n = 3)
were treated with either GW4064 (100 mg per kg body weight) or
vehicle three times as previously described [31] (first dose at 8 am,
second dose at 6 pm, third dose at 8 am the second day). Mice
were fasted overnight starting from the second dose and liver
tissues were collected at 2 hours after the third dose. All mice used
for microarray study were maintained in pathogen-free animal
facilities in the Laboratory of Animal Research, under a standard
12-hour light/dark cycle (6:00AM/6:00PM) with free access to
standard chow and autoclaved tap water. Animal protocols and
procedures were approved by the Institutional Animal Care and
Use Committee (IACUC) at the University of Kansas Medical
Center. Total RNA from livers was prepared with TRIzol
Reagent (Invitrogen, CA), and the whole transcription expression
levels were determined using Mouse Gene 1.0 ST Array system
manufactured by Affymetrix, Inc.. Microarray data were analyzed
using the Affymetrix Power Tools (http://www.affymetrix.com).
RNA-seq Data Analysis
For RNA-seq in PHHs, RNA was pooled from selected PHH
donors. After sequencing, the obtained reads were aligned to the
Homo Sapiens reference genome (hg19) using TopHat (version
2.0.0) [32]. The resulted alignments were then assembled into
transcripts using Cufflinks (version 2.0.2). Cuffdiff, a component of
the Cufflinks package, was used to estimate FPKM (fragments per
kilobase of exon model per million mapped fragments) and
identify differentially expressed transcripts. Finally the Baggerley’s
test was used to perform the differential expression analysis.
Pathway Analysis for ChIP-seq and RNA-seq
Functional genes from ChIP-seq and RNA-seq were selected
and analyzed using the Functional Annotation Tool in DAVID
((http://www.david.niaid.nih.gov). For a pathway or process to be
defined, the threshold count was set at 2 with a minimum EASE
(Expression Analysis Systematic Explorer) score, a modified Fisher
Exact Test, of 0.1. Categories from DAVID with false discovery
rates (FDRs) less than or equal to 0.1 were considered as
statistically significant.
Data Files Access
All sequencing data files discussed in this publication have been
deposited in NCBI’s Gene Expression Omnibus [33] and are
accessible through GEO Series accession number GSE57312
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE57312)
Statistical Statement
For RT-qRCR experiments, due to the difficulty of repeating
sample collection from individual PHH donors, PHHs from
different donors served as experimental replicates to validate FXR
activation for the pooled PHH samples.
Results
FXR Activation in PHHs
To identify genome-wide FXR binding sites in primary human
hepatocytes, we first validated FXR activation in the PHHs
obtained in this study. Upon 24 hours of GW4064 treatment,
mRNA levels of classic FXR target genes (BSEP, OST-b) were
induced in PHHs from individual donors (Figure S1A). Pooled
chromatin samples, which were collected after 1 hour GW4064
treatment, showed significant enrichment of FXR binding to
known FXR targets (promoter regions of BSEP and OST-b), but
not the negative control (promoter region of IL-8) (Figure S1B).
ChIPed-DNA, generated from pooled chromatin from selected
donors (Table S1), as well as pooled RNA was then used to
generate DNA and RNA sequencing libraries. Indeed, many
known human FXRREs were detected with relatively high peak
values in this study, in both DMSO and GW4064 treated PHHs
(Table 1). Again, multiple FXR binding sites were found in the
NR0B2 and OST-b gene in our datasets (Table 1), which
resembled the binding patterns of FXR to these genes in mice
[11].
In ChIP-seq, the peak summit of each peak (binding site) was a
single bp position within the peak with the highest coverage given
by the MACS analysis. Due to the relatively large size of
fragmented library DNA obtained in this study (average 350 bp
for ChIP-seq), and the subtle differences in the local chromatin
environment in different samples, we saw slightly different peak
width and peak summit values for the same binding sites in the two
datasets. For example, for the binding site located in the intron of
FGF19 gene, the peak width was 1000 and 851 bps in the ChIP-
seq datasets from DMSO treated PHHs (PHH-DMSO) and
GW4064 treated PHHs (PHH-GW), respectively. And the peak
summits in the two datasets were 3665 and 3695 bps downstream
from the TSS of FGF19, respectively. Nevertheless, these peaks
were indicating the same binding site.
Comparison of Global FXR Binding between PHHs and
Mouse Livers
When cut off score (CO score) for ChIP-seq data analysis was
set as 20, a total of 2759 and 5235 FXR binding sites were
identified from PHH-DMSO and PHH-GW, respectively. Human
and mouse FXR binding profiles in livers were compared between
these human data with our previous genome-wide mouse FXR
binding data, which were obtained from WT mice treated with
GW4064 (referred to as mLiver-GW, which was not normalized to
the rIgG control though) [11]. The following results were obtained
by comparing the global binding pattern in these datasets: 1st,
genomic distributions of FXR binding sites were similar in PHHs
compared to those in mice (Figure 1). Briefly, around 43% peaks
were located in intergenic, 21% in upstream 0-10 kb, 22% in
introns, 10% in downstream 0–10 kb, 2% in 59 untranslated
region (UTR), 1% in 39 UTR, and 1% in coding DNA sequence
(CDS) regions of their associated RefSeq genes in both PHH-
DMSO and PHH-GW. This site-distribution pattern was similar
to that in mice. Though in mouse livers, around 30% peaks were
located in introns and 15% in upstream 0–10 kb region [11]. 2nd,
the distribution patterns of total FXR binding sites relative to
transcription start sites (TSSs) of the associated RefSeq genes, and
FXR’s intron binding patterns were both similar to those in mice
as well. The highest frequency of total binding events was located
within 0–10 kb up and downstream of TSSs (Figure 2A). Most
intron binding events were located in the 1st intron and the
number of total binding events in individual intron decreased as
Genome-Wide Analysis of FXR Targets in PHHs
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the intron number increased (Figure 2B). These patterns were
almost identical to those in mice [11].
Motif Analysis of FXR Binding Sites in PHHs
The most commonly reported FXR binding motif is an IR1 in
both mice and humans. This motif has been reported in many
human FXR target genes, such as ABCB11, FGF19, NR0B2, and
OST-b [22,23,34]. When we select the top 500 peaks from PHH-
GW and PHH-DMSO, the most common motif found in PHH-
GW was an IR-1 with a putative nuclear half site, whereas in
PHH-DMSO it was the IR1 motif (Figure 3). And interestingly,
when we select the top 501–1000 peaks to run motif analysis, we
only obtained the IR-1 motif from both datasets (data not shown).
The presence of IR-1 with nuclear half site was also similar to our
previous motif analysis in mouse livers [11].
Validation of ChIP-seq and Novel FXR Targets
After motif analysis, we were able to precisely locate the IR-1
site associated with each peak summit for most peaks in our
datasets. The subtle position difference (mostly around 50 bp)
from the IR-1 site to the peak summit for each FXR target was
most likely caused by a combination of relatively large DNA
fragments used for our sequencing analysis and the technical
limitation of the sequencing processing and data analysis. Since
most classic FXR targets were presented correctly in the datasets
(Table 1), we then focused on validating novel FXR targets.
ChIP-qPCR was performed on chromatin samples from pooled
PHH samples, as well as individual PHH donors. For many FXR
targets, we were unable to detect valid Ct value from rIgG control
from qPCR experiments for individual PHH donors, mainly due
to limited quantity of chromatin samples. Nevertheless, we were
able to confirm enhanced FXR pull-down from GW4064 treated
PHHs comparing to DMSO control, for the promoter regions of
BSEP and most selected novel targets, but not the negative
controls. And for those FXR targets, of which FXR pull-down was
not further enhanced upon GW4064 treatment, we were able to
calculate their FXR pull-down efficiency after normalizing to rIgG
control from pooled PHH samples (Figure 4A, 4B). Without
valid Ct values from the rIgG control pull-down, we couldn’t
differentiate these FXR targets from the negative controls. For
exp., the binding score for PNMT (phenylethanolamine N-
methyltransferase) in PHH-DMSO and PHH-GW were 55 and
68, respectively, which were close. Indeed, ChIP-qPCR showed
similar FXR pull-down efficiency from pooled PHH samples
(Figure 4B, around 3 fold for both control and treatment). The
promoter region of OST-b showed the same trend as well
(Figure 1B). In this regard, to better illustrate FXR binding in
both DMSO and GW4064 treated PHHs, only ChIP-qPCR data
for pooled PHHs were presented. We were able to validate FXR
pull-down for most selected novel targets with relatively high
binding scores (9 out of 11 peaks were validated, with binding
Table 1. Selected previously reported FXR target genes identified in this study*.
PHH-DMSO PHH-GW
Gene Distance To TSS Binding Score Distance To TSS Binding Score
ABCB11 283 69 2103 319
FGF19 3665 89 3695 251
ICAM1 58 91 88 111
MIR122 236936 89 236941 294
NR0B2 2258 83 2178 112
3252 41 3212 69
OST2b 248 67 17 68
10087 67 10017 138
PPARa 22839 126 22789 203
* Distance To TSS is the distance of the peak of the binding site to the transcription start site (TSS) of the corresponding RefSeq gene. Note that the peak identified from
ChIP-seq analysis may not overlap exactly with the IR-1 motif found from motif analysis. The binding score is the FXR antibody pull-down score normalized to rIgG
control antibody generated by the sequencing analysis processes. Note that for most FXR targets listed, the binding score retrieved from PHH-GW dataset is much
larger than the score from PHH-DMSO for the same peak. This is a general trend for most shared FXR targets between the two datasets. Genes with their full names:
MIR122 (microRNA 122), PPARa (peroxisome proliferator-activated receptor alpha).
doi:10.1371/journal.pone.0105930.t001
Figure 1. Genomic distribution of FXR binding sites in PHH-
DMSO and PHH-GW. Percentage of FXR binding sites in the two
datasets that were distributed to .10 kb from genes (intergenic), 0–
10 kb upstream of genes (Up 0–10 kb), 59UTRs, coding sequence (CDS),
introns, 39UTRs, and 0–10 kb downstream of genes (Down 0–10 kb)
were shown. The cut off score for the data analysis presented in
Figure 1, 2, 3 and 5 were 20 from ChIP-seq data analysis.
doi:10.1371/journal.pone.0105930.g001
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scores equal to or above 50 in either PHH-DMSO or PHH-GW
(Figure 4A). This trend was consistent with our previous findings
in mouse livers [11].
Microarray, RNA-seq and their Correlation with ChIP-seq
Datasets
Using microarray, we obtained a gene expression profile from
WT mouse livers treated with GW4064 (M-mLiver-GW) normal-
ized to vehicle control. When set cut off fold induction (CO fold) as
1.5 and p-value ,0.05 (unpaired t-test), we obtained 102 different
Figure 2. Distribution of total FXR binding sites relative to TSSs, and intron binding profiles of FXR in the two datasets. (A) The left
panel shows the frequency distribution of FXR binding. The number of binding events (y-axis) was plotted against the distance from TSSs in 10 kb
increments (x-axis) for PHH-DMSO and PHH-GW. (B) The cumulative binding events of FXR distributed only to introns of RefSeq genes in the two
datasets. The graph displays the total number of FXR binding peaks (y-axis) in PHH-DMSO and PHH-GW located within intron 1-9 of RefSeq genes (x-
axis). Total of 62.4% and 60.2% of intron binding events were located in the first introns in PHH-DMSO and PHH-GW, respectively.
doi:10.1371/journal.pone.0105930.g002
Figure 3. Motif analysis. The most commonly identified sequence motifs from the top 500 FXR binding sites in the two datasets using MEME.
These motifs were found in totally 247, 240 sites in PHH-DMSO, PHH-GW from the top 500 peaks (p-value,1.00e-5), respectively. It is interesting that
there is a putative nuclear half site next to the IR-1 site from PHH-GW, but not in PHH-DMSO.
doi:10.1371/journal.pone.0105930.g003
Genome-Wide Analysis of FXR Targets in PHHs
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genes with altered expression levels, up or down more than or
equal to 1.5 fold. From RNA-seq for GW4064-treated PHHs (R-
PHH-GW), which was normalized to DMSO control, we obtained
143 genes with log2 fold enrichment $2 (fold change$4, both up-
and down- regulated) and p-value ,0.05. The percentage of genes
found in microarray and RNA-seq, which were also bound by
FXR from ChIP-seq, was plotted in Figure 5 based on the fold
induction from microarray and RNA-seq. Among all the genes
found in M-mLiver-GW, over 50% were bound in mLiver-GW
for both up- and down- regulated. However in R-PHH-GW,
around 50% up-regulated genes were bound in PHH-GW,
whereas only a few down-regulated genes were actually bound
in PHH-GW. Interestingly, FGF19 and CYP7A1 (cytochrome
P450, family 7, subfamily A, polypeptide 1) were the top up- and
down-regulated FXR targets in R-PHH-GW, respectively.
Pathway Analysis for ChIP-seq and RNA-seq
A major difference between the mLiver-GW dataset and the
PHH-GW dataset was that, more than 5,000 genes and 10,000
peaks were found in mLiver-GW compared to 5,231 peaks
identified in PHH-GW. The lack of IgG control for the mLiver-
GW may well explain this major difference as non-specific peaks
may present in the mouse FXR binding study. Another difference
was that the majority of the peaks in mLiver-GW were associated
with RefSeq genes, which encode proteins with known functions,
whereas in PHH-GW only around 50% peaks were.
In order to compare and contrast the functional detail of FXR
binding in humans and mice, two major analyses from DAVID
were performed, the Kyoto Encyclopedia of Genes and Genomes
(KEGG) and the Gene Ontology Biological Process (GO-BP)
analysis. Similar to our previous study, functional genes associated
with peaks located in the upstream 0-10 kb promoter regions were
selected to run DAVID analyses. Overall, more categories were
enriched in PHH-GW than PHH-DMSO. And most categories
enriched in PHH-DMSO were also presented in PHH-GW. In
this regard, only categories and their corresponding FXR targets
from PHH-GW were presented and compared with mLiver-GW.
All significantly enriched KEGG categories (with FDR ,0.1)
(Table 2A), and the corresponding genes (Table S3A) obtained
were listed, whereas most non-redundant categories (with gene
count .5) from GO-BP were presented (Table 3B, S3B). From
DAVID analyses, we could see overall similar pathways enriched
from mLiver-GW and PHH-GW, though the number of genes
retrieved from PHH-GW was smaller. Nevertheless, the percent-
age of genes found in each category was similar between the two
datasets.
For R-PHH-GW, 291 functional genes with log2 fold $1 (fold
change $2, up- and down- regulated), and p-value #0.05 were
retrieved for KEGG and GO-BP analyses. Note that the cut off
fold change used for pathway analysis is smaller than the cut off
used for the ChIP-seq/RNA-seq correlation analysis. For pathway
analysis, the cumulative effect from many altered genes in a single
pathway could be of functional importance as well, though the
level of fold change for individual gene was relatively low. All
categories from KEGG and non-redundant categories from GO-
BP, and the corresponding genes were presented (Table 3A, 3B).
In agreement with previous correlation study presented in
Figure 5, both similar and different categories were enriched
from R-PHH-GW. Interestingly, many genes involved in chemo-
kine signaling pathway (KEGG) and chemotaxis (GO-BP) were
enriched in R-PHH-GW (Table 3), and most of these were not
directly bound by FXR.
Figure 4. ChIP-seq validation. The location of FXR binding sites (second column on the left) and binding scores (the two columns on the right) for
the selected novel FXR targets found in PHH-DMSO and PHH-GW were summarized in (A), and ChIP-qPCR results for these targets from pooled
GW4064 or DMSO treated PHHs were presented in (B). FXR pull-down was normalized to rabbit immunoglobulin G control. Note that ACTBP11 is a
pseudogene in humans. GW4064 treatment also induced the mRNA levels of AOC3, FABP3, PNMT and UROC1 in PHHs in RNA-seq (data not shown).
*N/F stands for not found. Genes with their full names: ACTBP11 (actin, beta pseudogene 11), AOC3 (amine oxidase, copper containing 3), FABP3 (fatty
acid binding protein 3), HS6ST1 (heparan sulfate 6-O-sulfotransferase 1), GFOD2 (glucose-fructose oxidoreductase domain containing 2), PNMT
(phenylethanolamine N-methyltransferase), and UROC1 (urocanate hydratase 1).
doi:10.1371/journal.pone.0105930.g004
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Discussion
In this study, combining the widely used ChIP-seq and RNA-
seq techniques, we have characterized the genome-wide FXR
binding and transcriptome profiles upon ligand activation in
selected PHHs. We detected almost all previously identified
important human FXR targets, which have diverse physiological
functions. Comparing the global FXR binding patterns, we
showed that the patterns in PHHs were very similar to those
identified in mouse livers in terms of genomic distribution, intron
binding pattern, and the association with TSSs of RefSeq genes.
These phenomena were in agreement with the conserved function
of FXR in transcriptional regulation.
Most convincingly, the motifs found in this study were almost
identical to those found in mice. Interestingly, the putative nuclear
receptor half site was enriched significantly only from the top 500
peaks in PHH-GW, neither in the top 501 to 1000 peaks nor the
top 500 peaks from PHH-DMSO (Figure 3). In the chromatin
level, the co-binding of FXR and other transcription factors to
certain targets may potentially correspond to higher levels of pull-
down from ChIP assay, leading to higher enrichment scores for
these genes. Previous genome-wide binding analysis of LRH-1 in
mice has shown that LRH-1 could bind to the nuclear half site
next to IR1, and co-regulate transcription of FXR target genes
involved in lipid metabolic processes in mice [16]. The top 500
peaks identified in this study are associated with genes not only
involved in lipid metabolism, but in diverse cellular processes. This
could indicate a common mechanism of how FXR regulate gene
transcription in different cellular processes, while with different
cofactors involved. This type of co-regulation has been well studied
for ERa [35]. Moreover, the presence of a nuclear receptor half
site adjacent to the IR-1 in both PHH-GW and mLiver-GW
indicates the similarities of FXR functions from mice to humans in
a greater extent by indicating the existence of similar type of
cofactors for FXR in different species. This mechanistic similarity
implicates that tissue- and even pathway- specific FXR modulation
in mice can be translated into therapeutic benefits in humans.
Using multiple pathway analysis tools (KEGG and GO-BP from
DAVID), the current study predicts that human FXR could
participate in the regulation of diverse physiological processes
(Table 2, S3). Furthermore, similar pathways were enriched from
PHH-GW compared to mLive-GW. More genes were obtained
from mLiver-GW than PHH-GW. As a result, more pathways
were enriched in mLiver-GW [11]. Future studies are needed in
order to determine to what degree the lack of IgG control
contributes to the increased output from mLiver-GW. Overall, the
comparison studies presented in this study will be valuable
information for researchers in correlating and translating previous
and future mouse FXR studies to human FXR functions.
RNA-seq analysis for DMSO and GW4064 treated PHHs also
further confirmed the reliability of GW4064 treatment and FXR
activation in this study. Interestingly, FGF19 and CYP7A1 were
the top up-regulated and down-regulated target genes in PHHs,
Figure 5. Correlation of FXR binding with target gene expression. The binding of FXR to its target genes were correlated with genes that
showed altered mRNA expression levels in RNA-seq for PHHs (R-PHH-GW) and microarray for mouse livers (M-mLiver-GW). The x axis displays the
divided range of fold induction in R-PHH-GW or M-mLiver-GW. For RNA-seq, 143 altered genes with log2 fold change $2 (fold change $4, both up-
and down- regulated), p-value,0.05 were used, whereas for microarray, 102 altered genes with fold change.1.5 (both up- and down- regulated), p-
value ,0.05 were used. The total number of genes from microarray or RNA-seq analysis in each fold range was listed in parenthesis. The y axis
displays the percentage of genes found in M-mLiver-GW and R-PHH-GW, which were also bound by FXR in PHH-GW (top) and mLiver-GW (bottom).
Note that for the y axis, the log2 fold change from RNA-seq data analysis was displayed for R-PHH-GW, while for M-mLive-GW, the actual fold change
generated from microarray data analysis was displayed.
doi:10.1371/journal.pone.0105930.g005
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respectively, whereas in mice Fgf15 is only found to be expressed
and induced in the intestine [31].
When correlating the results from ChIP-seq with RNA-seq for
PHHs, and microarray for mouse livers, different trends were
observed for genes down-regulated following GW4064 treatment
(Figure 5). In addition, only a small portion of target genes
showed similar change in R-PHH-GW and M-mLiver-GW. This
difference may be due to several reasons. First, there are different
baseline regulatory network in different species, such as the
different expression patterns of FGF19 in humans versus Fgf15 in
mice. Besides, the genetic background of the PHH donors could
be heterogeneous since we didn’t receive certain donor informa-
tion upon tissue collection, such as races, patient condition, etc.
And the inbred C57BL6/J mice were relatively homogenous.
Second, for many FXR target genes, the expression levels may be
already high in control mice due to activation of FXR by the
largely stable bile acid pool, while the levels of residual bile acids in
PHHs could be very low. In this regard, GW4064 treatment
wouldn’t further induce the expression of these genes in mice. In
line with this, for many FXR target genes in mice, we detected
similar FXR binding from ChIP assay when comparing GW4064
treated versus vehicle control treated mouse livers (data not
shown). But we did see dramatic increase of FXR binding from
GW4064 versus DMSO treated PHHs (see data in Table 1,
Table 2. Comparison of DAVID Functional Annotation for PHH-GW versus mLiver-GW*.
A. KEGG analysis
mLiver-GW (Total 970 genes) PHH-GW (Total 343 genes)
Term Count % FDR Count % FDR
Retinol metabolism 12 2.836879433 0.000335516
Drug metabolism 23 1.82E+00 0.000169359 12 2.836879433 0.001458046
Complement and coagulation cascades 21 1.660079051 0.003343182 11 2.600472813 0.029459911
Metabolism of xenobiotics by cytochrome P450 18 1.422924901 0.030917603 10 2.364066194 0.057413681
PPAR signaling pathway 26 2.055335968 4.11311E-06 7 1.654846336 1.58E+01
B. GO-BP analysis
mLiver-GW (Total 970 genes) PHH-GW (Total 343 genes)
Term Count % FDR Count % FDR
organic ether metabolic process 11 0.869565 3.11774 13 3.073286 0.0000104
triglyceride metabolic process 11 0.869565 0.268143 12 2.836879 0.0000112
glycerolipid metabolic process 21 1.660079 1.408123 19 4.491726 2.53E-04
lipid transport 26 2.06E+00 0.001436 18 4.255319 2.58E-04
chemical homeostasis 45 3.557312 0.750307 31 7.328605 0.029556
monocarboxylic acid transport 8 0.632411 0.387526 9 2.12766 0.057257
response to wounding 53 4.189723 0.000434 30 7.092199 0.138013
oxidation reduction 86 6.798419 0.000218 34 8.037825 0.138493
cholesterol metabolic process 17 1.34E+00 0.045242 11 2.600473 1.88E-01
homeostatic process 70 5.53E+00 0.036206 37 8.747045 2.92E-01
steroid metabolic process 41 3.241107 2.94E-09 16 3.782506 0.337117
cellular amino acid derivative metabolic process 29 2.29249 0.00108 12 2.836879 5.666095
fatty acid metabolic process 41 3.241107 0.000000255 11 2.600473 40.37399
regulation of cellular ketone metabolic process 8 0.632411 1.457816 9 2.12766 0.151048
acute-phase response 14 1.11E+00 0.0000783 9 2.12766 1.02E-02
acute inflammatory response 26 2.06E+00 0.000000314 10 2.364066 1.44E+00
coenzyme metabolic process 30 2.371542 0.000427 9 2.12766 51.62624
organic acid catabolic process 27 2.134387 5.02E-08
glucose metabolic process 32 2.529644 0.000019
cellular amino acid catabolic process 19 1.501976 0.000029
hexose metabolic process 35 2.77E+00 0.0000489
monosaccharide metabolic process 36 2.85E+00 0.000351
L-phenylalanine catabolic process 6 0.474308 0.018543
pyruvate metabolic process 10 0.790514 0.059427
*Binding sites that were associated with 0-10 kb upstream of RefSeq genes were selected for DAVID functional annotation analyses. The cut off score for ChIP-seq
datasets was 20. Totally 970 and 343 RefSeq genes were retrieved from mLiver-GW and PHH-GW, respectively. The categories were listed based on the FDR values from
DAVID analyses for PHH-GW dataset.
doi:10.1371/journal.pone.0105930.t002
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Figure 4 and Figure S1). Indeed, both the magnitude of relative
fold change levels and the number of altered genes were much
larger in R-PHH-GW than M-mLiver-GW. Third, gene expres-
sion in the mouse livers could be affected by whole body
physiology, such as circadian rhythms, hormones, fast/feeding
cycles, physical activity and energy level, etc. Fourth, for
microarray study, we cannot completely rule out the contributions
from other cell types in mouse livers, such as endothelial cells and
liver Kupffer cells, while in the enriched PHHs, the number of
other liver cell types was minimal. Finally, technical differences
between RNA-seq and microarray could be another minor factor
as well. Among all these factors, the first two that affecting the
baseline expression levels of many FXR target genes, could be the
major causes of the differences we saw between the in vivo and in
vitro studies. While certain technical limitations existed, the
correlation/comparison study still provides valuable information
for human FXR function. For R-PHH-GW, mRNA level down-
regulation was observed for only a few FXR target genes found in
ChIP-seq. But for M-mLiver-GW, the percentage of up- and
down- regulated genes also presented in ChIP-seq was similar. Lee
et al have shown that direct gene suppression by FXR is common
in mice [13]. The correlation study presented here implicates that
FXR may play less important roles in direct gene suppression in
humans.
The FXR gene sequence is highly conserved across species, and
the protein sequence is very similar between humans and mice
[36,37]. This similarity indicates the overall conserved and
important functions of FXR in different species, further confirmed
by our genome wide binding studies. On the other hand, the
differences between species, from genome landscape, cellular
components, all the way to physiology and pathology could
contribute to the differences identified in this study, especially for
gene expression.
In summary, we have obtained valuable information of genome-
wide binding and transcriptome analyses of human FXR in PHHs.
Detailed analysis of the ChIP-seq data indicates that the global
binding patterns of FXR in PHHs are similar to those in mouse
livers. In addition, similar biological pathways were enriched from
genes bound by FXR in PHHs compared to those enriched in
mouse livers. We also identified and validated novel FXR target
genes, with and without alteration of mRNA levels. Species
differences were found for specific pathways and within gene
families involved in similar pathways. In a major extent, mouse
model is a suitable model for studying human FXR functions.
Supporting Information
Figure S1 Validation of FXR activation in individual
PHH donors and pooled PHH chromatin. (A) Relative
mRNA levels of FXR and FXR targets (BSEP, OST-b) in the
selected four PHH donors (1958, 1959, 1962, and 1974) upon
24 hr GW4064 treatment normalized to DMSO control by RT-
qPCR analysis. For each PHH donors, we treated 3 wells of cells
with GW4064, 3 with DMSO control. RNA from each well was
collected and analyzed individually. Human 18S was used as the
normalization control. (B) ChIP-qPCR analysis of FXR antibody
Table 3. DAVID functional annotation for PHH RNA-seq*.
A. KEGG analysis
Term % Genes
Retinol metabolism 2.9508 CYP1A1, CYP26B1, ADH1C, DHRS9, ADH1B, CYP26A1, CYP2A7, CYP1A2, UGT2B10, RDH16
Cytokine-cytokine receptor interaction 4.918 CXCL2, CX3CL1, EDAR, CCL15, CCL18, CXCL10, INHBB, CCL25, TNFRSF9, INHBA, TNFSF10,
TNFRSF1B, CCL14, CCL20, CXCL13, IL1B
PPAR signaling pathway 1.9672 PPARD, HMGCS2, CYP7A1, FABP3, FABP6, ANGPTL4
Steroid hormone biosynthesis 1.6393 HSD3B2, CYP1A1, CYP7A1, UGT2B10, SULT1E1
Tryptophan metabolism 1.3115 KYNU, CYP1A1, IDO2, CYP1A2
Drug metabolism 1.3115 XDH, UPP1, CYP2A7, UGT2B10
Tyrosine metabolism 1.3115 PNMT, ADH1C, ADH1B, TAT, AOC3
Calcium signaling pathway 2.623 ADRB1, CYSLTR1, PHKA1, CACNA1H, BDKRB2, VDAC1P1, ITPKA, HTR2A
Chemokine signaling pathway 2.623 CCL25, CCL14, CCL20, CXCL13, CXCL2, CX3CL1, CCL15, CCL18, CXCL10
B. GO-BP analysis
Term % Genes
chemotaxis 4.2623 CYSLTR1, CXCL2, CX3CL1, CCL15, CCL18, CXCL10, CCL25, CCL14, CCL20, CXCL13, IL1B,
LECT2, DEFB1, FGF2
oxidation reduction 7.8689 HSD3B2, XDH, ALDH8A1, STEAP4, ADH1C, ADH1B, BBOX1, CYP7A1, CYP26B1, HSD17B6,
LOXL4, ALDH6A1, CYP1A1, IDO2, DHRS9, CYP26A1, CYP1A2, CYP27C1, DIO3, ALOX15B,
HAO2, CYP2A7, RDH16, DCXR, AOC3
ion homeostasis 5.2459 KNG1, MCHR1, PPARD, CYSLTR1, ATP1A2, BDKRB2, CCL15, S1PR3, CCL14, RHCG, CXCL13,
MT2A, LGI4, IL1B, NPPB, NEDD4L, MT3
immune response 5.9016 ICAM1, KYNU, IGHG4, AQP9, CXCL2, CX3CL1, CCL15, CCL18, CXCL10, CCL25, TNFSF10,
TNFRSF1B, CCL14, CCL20, CXCL13, SEMA7A, IL1B, DEFB1, CD14
regulation of programmed cell death 6.5574 KNG1, NUAK2, EEF1A2, BCL2A1, ACTN2, BDKRB2, SOX9, DAPK2, GDNF, INHBA, SERPINB9,
TNFRSF9, TNFSF10, ALOX15B, TNFAIP8, IL1B, CFDP1, FGF2, PHLDA1, ANGPTL4
*Functional genes with log2 fold enrichment $1 (fold change $2, both up- and down- regulated) and p-value ,0.05 were selected for DAVID analysis, totally 291
RefSeq genes were retrieved from the PHH RNA-seq dataset (R-PHH-GW).
doi:10.1371/journal.pone.0105930.t003
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pull-down for the promoter regions of BSEP, OST-b and IL-8
upon 1 hr DMSO or GW4064 treatment for pooled chromatin
from the selected 4 donors in (A). Fold enrichment of FXR binding
was normalized to rabbit immunoglobulin-G control antibody.
(TIF)
Table S1 Summary of PHH Donors.
(DOCX)
Table S2 Primers Used for Quantitative PCR.
(DOCX)
Table S3 Comparison of Genes from Selected Catego-
ries in DAVID Anotation for ChIP-seq.
(DOCX)
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